Novel Psychoactive Substances

Professor Dargan and Dr Wood are both expert advisors on novel psychoactive substances to expert bodies in the UK (Advisory Council on the Misuse of Drugs, ACMD), Europe (European Monitoring Centre for Drugs and Drug Addiction, EMCDDA) and Worldwide (United Nations Office on Drugs and Crime, UNODC). They run a clinical service managing patients with acute drug toxicity, and have a clinical and research interest in novel psychoactive substances. They publish widely in this field and have both been invited to give keynote lectures at International meetings on this topic. David Wood is a Consultant Physician and Clinical Toxicologist at Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK.

I. Background 1. Legal Classification and International Systems for Monitoring Novel Psychoactive Substances 2. Availability and Supply of Novel Psychoactive Substances 3. Prevalence of Use of Novel Psychoactive Substances 4. Pharmacological Profiling of Novel Psychoactive Substances 5. Novel methods of NPS detection and data triangulation 6. Social issues in the use of novel psychoactive substances 7. General management of the patient with Novel Psychoactive Substance Toxicity 8. Addiction and treatment of Novel Psychoactive Substance dependence

II. Analytical Techniques 9. Analytical techniques for the detection of novel psychoactive substances and their metabolites

III. Individual Novel Psychoactive Substances 10. Synthetic Amphetamines including novel MDMA analogues 11. Pharmacology and Toxicology of N-Benzyl-phenylethylamines (25X-NBOMe) Hallucinogens 12. 1-Benzylpiperazine and other Piperazine-based stimulants 13. Cathinones 14. Arylcyclohexamines 15. Synthetic cannabinoids 16. Novel opioids 17. Novel benzodiazepines 18. Tryptamines